



University of Groningen

To the editor

Lokhorst, Henk M.; Hazenberg, Bouke P.C.; Croockewit, Alexandra

Published in: New England Journal of Medicine

DOI: 10.1056/NEJMc072918

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2008

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): Lokhorst, H. M., Hazenberg, B. P. C., & Croockewit, A. (2008). To the editor: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. *New England Journal of Medicine, 358*, 92. https://doi.org/10.1056/NEJMc072918

Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverneamendment.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

TO THE EDITOR: Jaccard et al. (Sept. 13 issue)¹ report on a difficult trial comparing high-dose melphalan with melphalan plus dexamethasone in patients with immunoglobulin-light-chain (AL) amyloidosis, but their results must be interpreted with caution. The treatment-related mortality rate (24%) in the group that received high-dose melphalan is more than twice the rate in centers performing transplantations for AL amyloidosis.² The study by Jaccard et al. enrolled many patients with involvement of three or more organs (36%) and poor cardiac status, thereby introducing a bias in favor of melphalan plus dexamethasone.² Moreover, 10 of 37 patients in the group treated with high-dose melphalan received an inadequate dose of melphalan (140 mg per square meter of bodysurface area).³ The results underscore the lack of benefit of high-dose melphalan in high-risk patients but do not address the role of high-dose melphalan in lower-risk patients.

Shaji Kumar, M.D. Angela Dispenzieri, M.D. Morie A. Gertz, M.D.

Mayo Clinic Rochester, MN 55905 kumar.shaji@mayo.edu

1. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-93.

2. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549-55.

3. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025-31.

TO THE EDITOR: The French multicenter study reported by Jaccard et al. showed no difference between high-dose melphalan and melphalan plus dexamethasone in AL amyloidosis. This finding raises questions concerning the management of life-threatening diseases. Should patients with rare diseases such as amyloidosis be treated anywhere (the average center enrolled <1 patient annually) or only at experienced referral centers?¹ Does the need for simple treatment options that can be delivered anywhere and to everyone negate the need to develop intensive (and potentially toxic) options that may provide additional therapeutic benefit for se-

lected patients? Transplant-related mortality is substantially higher at low-volume, inexperienced centers¹ — very likely a concern with most of the study centers.

It is unclear whether the groups in the French study were truly comparable, since no information was provided on levels of the N-terminal fragment of B-type natriuretic peptide and troponin T, biomarkers shown to be of critical prognostic significance in amyloidosis.²

Jayesh Mehta, M.D. Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, IL 60611

j-mehta@northwestern.edu

1. Mehta J. High-dose therapy for amyloidosis. Blood 2004; 104:2993-4.

2. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520-30.

TO THE EDITOR: Despite the absence of comparative trials, stem-cell transplantation has been adopted widely in the treatment of AL amyloidosis, particularly in North America, but it has been associated with procedural mortality of more than 13%, even in specialist centers. In contrast, chemotherapy without transplantation has been favored in the United Kingdom, where the median survival exceeded 60 months and treatment-related mortality was less than 7% among 448 patients with AL amyloidosis who received such regimens.1 Furthermore, a complete clonal response is not always necessary for long-term survival, since one third of patients with AL amyloidosis at our center who survived for longer than 10 years had only a partial hematologic response. The findings of our open but relatively large studies thus accord with those of the study by Jaccard et al. and, outside the context of much-needed larger clinical trials, support cyclic chemotherapy guided by frequent assessments of serum free immunoglobulin light chains and organ function, weighed cycle by cycle against treatment-related toxicity.²

Helen J. Lachmann, M.D. Ashutosh D. Wechalekar, M.D. Julian D. Gillmore, M.D., Ph.D. U.K. National Amyloidosis Centre London NW3 2PF, United Kingdom h.lachmann@medsch.ucl.ac.uk

N ENGL J MED 358;1 WWW.NEJM.ORG JANUARY 3, 2008

The New England Journal of Medicine

Downloaded from nejm.org at University of Groningen on March 11, 2022. For personal use only. No other uses without permission.

Copyright © 2008 Massachusetts Medical Society. All rights reserved.

2. Guidelines Working Group of UK Myeloma Forum, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004;125:681-700.

TO THE EDITOR: The inferior survival (median, 22 months) of patients treated with high-dose melphalan for AL amyloidosis, as reported by Jaccard et al., is probably due to the design of the study. Intensive treatment of AL amyloidosis is a challenge; in the French trial, there were 50 intended transplantations during 5 years in 29 centers, and treatment delay may have contributed to the high treatment-related mortality in the high-dose melphalan group.

In the prospective multicenter trial conducted by the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), 70 previously untreated patients with AL amyloidosis (World Health Organization performance-status score, 0 to 2), 47% of whom had cardiac involvement and more than 55% of whom had high-risk disease,1 received vincristine, doxorubicin, and dexamethasone (VAD), followed in 47 patients by high-dose melphalan (140 to 200 mg per square meter). The transplantations were performed in tertiary referral centers. Nine patients died from treatment-related causes (13%): seven during treatment with VAD and two after treatment with high-dose melphalan. The 4-year overall survival rate among all the patients was 62%, while the 4-year survival rate after transplantation was 78%.

We believe that there is still insufficient evidence that intensive therapy for AL amyloidosis should be abandoned.

Henk M. Lokhorst, M.D., Ph.D. University Medical Center Utrecht 3584 CX Utrecht, the Netherlands h.lokhorst@umcutrecht.nl

Bouke P.C. Hazenberg, M.D., Ph.D. University Medical Center Groningen 9700 RB Groningen, the Netherlands

Alexandra Croockewit, M.D., Ph.D. University Medical Center Nijmegen 6525 GA Nijmegen, the Netherlands

1. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001;19:3350-6. TO THE EDITOR: The French phase 3 trial of stemcell transplantation for systemic AL amyloidosis shows the morbidity that results when the treatment of patients with multiorgan dysfunction is based on criteria for transplantation that are "not as stringent as those used in large North American centers."1,2 We have completed a phase 2 trial testing risk-adapted stem-cell transplantation and adjuvant chemotherapy in 45 patients with newly diagnosed, untreated AL amyloidosis (NCT00089167). Aggressive supportive measures minimized the morbidity associated with granulocyte colony-stimulating factor and gastrointestinal bleeding, and there was a stopping rule for a rate of treatment-related morbidity exceeding 10%. The rate of treatment-related morbidity was 4%; the rates of overall and complete hematologic responses were 79% and 38%, respectively; and the rate of organ responses was 48%.³ Median survival is undefined and for patients with cardiac involvement exceeds 3 years.

Raymond L. Comenzo, M.D. Richard M. Steingart, M.D. Adam D. Cohen, M.D. Memorial Sloan-Kettering Cancer Center New York, NY 10021 comenzor@mskcc.org

 Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82.
Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.

3. Cohen AD, Zhou P, Chou J, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/– thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007;139:224-33.

THE AUTHORS REPLY: The comments about our report mainly concern patient selection and the multicenter nature of our study. We addressed the critical issue of patient selection by means of a subgroup analysis using the Mayo Clinic criteria.¹ For patients with high-risk disease, the results confirmed the lack of benefit of high-dose melphalan, as already suggested by others.² For patients with low-risk disease (59 patients, including 27 with only one involved organ, who received mainly 200 mg of melphalan per square meter when treated in the high-dose group), the survival curves showed a nonsignificant difference in favor of oral melphalan plus high-dose oral dexamethasone, challenging the use of high-dose melphalan in this group of patients. For patients

N ENGLJ MED 358;1 WWW.NEJM.ORG JANUARY 3, 2008

The New England Journal of Medicine

Downloaded from nejm.org at University of Groningen on March 11, 2022. For personal use only. No other uses without permission.

Copyright © 2008 Massachusetts Medical Society. All rights reserved.

^{1.} Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457-64.

treated with oral melphalan plus high-dose oral dexamethasone, the 3-year overall survival rate was 80%, showing that they were actually "good risk" patients. With censoring of data for patients who died early and patients who could not receive their assigned treatment, the results of the landmark analysis strongly argued against the superiority of high-dose melphalan, even in groups with 0% treatment-related mortality and 100% treatment feasibility. This probably resulted from the very similar hematologic response rates in the two treatment groups, in a disease in which a clonal response is mandatory for improved survival.

Our 24% rate of treatment-related mortality with high-dose melphalan is in keeping with the results of several other multicenter studies and can be considered as representative of the results with high-dose melphalan when used outside some tertiary referral centers. The better results obtained in these referral centers probably reflect not only better management of the disease but also better selection of candidates for high-dose melphalan. Both were likely factors in the impressive results reported by Comenzo et al. Studies comparing new standard-dose regimens with (optimized) high-dose treatments should now be performed in tertiary referral centers. In our opinion, further improvements in the survival of patients with AL amyloidosis are likely to result from the use of new drugs and innovative therapeutic approaches.

Arnaud Jaccard, M.D. Centre Hospitalier Universitaire 87000 Limoges, France arnaud.jaccard@chu-limoges.fr

Philippe Moreau, M.D. Centre Hospitalier Universitaire 44000 Nantes, France

Jean-Paul Fermand, M.D. Hôpital Saint-Louis 75010 Paris, France

1. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001;19:3350-6.

2. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82.

Early Thimerosal Exposure and Neuropsychological Outcomes

TO THE EDITOR: Thompson et al. (Sept. 27 issue)¹ report the results of a study investigating the neuropsychological outcomes of early exposure to thimerosal. As a dissenting member of the panel of external consultants for this study, I object to the authors' conclusion that there is no causal association between thimerosal and children's brain function. The sample comprised children who were least likely to exhibit neuropsychological impairments. Specifically, children with congenital problems, those from multiple births, those of low birth weight, and those not living with their biological mother were excluded. The sample was skewed toward higher socioeconomic status and maternal education — factors that are associated with lower rates of neurobehavioral problems and higher intervention rates and that were not measured. The sampling frame included only children enrolled from birth in the health maintenance organization (HMO) and still enrolled after 7 to 10 years, excluding children in higher-mobility families, who tend to have lower academic and behavioral function.² Children with neurobehavioral problems may have been less likely to remain with the HMO. Only 30% of families selected for recruitment participated, a low rate for scientific research. Among the families selected for recruitment, 26% refused to participate. Another 28% "could not be located," which included families that did not respond to multiple recruitment attempts (internal documentation from the study contractor, Abt Associates) — another form of refusal.

Sallie Bernard, B.A. SafeMinds Aspen, CO 81611 sbernard@safeminds.org

1. Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 2007;357:1281-92.

2. Rumberger RW. Student mobility and academic achievement. In: Child & adolescent development. MentalHelp.net. January 23, 2003. (Accessed December 12, 2007, at http://mentalhelp.net/poc/ view_doc.php?type=doc&id=2084&cn=28.)

TO THE EDITOR: Recently, I summarized several nutritional factors that are likely to play a large

N ENGL J MED 358;1 WWW.NEJM.ORG JANUARY 3, 2008

The New England Journal of Medicine

Downloaded from nejm.org at University of Groningen on March 11, 2022. For personal use only. No other uses without permission.

Copyright © 2008 Massachusetts Medical Society. All rights reserved.